Sarepta Therapeutics, Inc. (SRPT)
| Previous close | 116.55 |
| Open | 116.55 |
| Bid | 107.67 x 200 |
| Ask | 114.90 x 100 |
| Day's range | 114.54 - 117.74 |
| 52-week range | 55.25 - 159.89 |
| Volume | |
| Avg. volume | 844,083 |
| Market cap | 10.776B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.80 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 165.89 |
Insider Monkey10 Unstoppable Stocks That Will Make You Richer
In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out with stocks tumbling as the S&P 500 recorded its worst day since […]
Investor's Business DailyWhy Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
